Anti-hCD20-mIgG2a Unit size Cat. code Docs Qty Price
100 µg

Monoclonal mouse IgG2a antibody against human CD20

Anti-hCD20-mIgG2a features the constant region of the mouse IgG2a isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukaemia.
Anti-hCD20-mIgG2a was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

Back to the top


Clonality: Monoclonal antibody
Specificity: Targets cells expressing human CD20
Isotype: Mouse IgG2a

Back to the top


100 µg purified anti-hCD20-mIgG2a antibody, provided azide-free and lyophilized

Back to the top


Customer Service
& Technical Support

In order to prevent automated spam submissions, please answer the following question:
3 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Shopping cart is empty